Role of pemetrexed and platinums combination in patients with non-small cell lung cancer - PubMed

Review

Role of pemetrexed and platinums combination in patients with non-small cell lung cancer

Manyin Chen et al. Curr Drug Targets. 2010 Jan.

Abstract

The incidence of lung cancer in 2007 is estimated to be 213,380 with 160,390 deaths in the United States. It will contribute to 31% of male and 26% of female cancer-related deaths and is the largest cause of cancer-related mortality in both men and women. Despite some advances in the treatment of advanced non-small cell lung cancer (NSCLC), the introduction of third-generation cytotoxic agents (vinorelbine, gemcitabine, docetaxel, irinotecan, and paclitaxel) has not achieved a breakthrough in the dismal prognosis of this disease. Several meta-analyses have proved the superiority of 2-drug chemotherapy and cisplatin-based chemotherapy, but no gold standard exists. This paper summarizes the clinical data of a new cytotoxic agent, pemetrexed, and its combination with platinums in the treatment of NSCLC. The addition of the vascular endothelial growth factor (VEGF) inhibitor (bevacizumab) or an EGFR-targeted drug (cetuximab) to pemetrexed/platinum in NSCLC, and the role of pemetrexed/platinum in adjuvant chemotherapy for early-stage NSCLC were also discussed in this paper.

Similar articles

• The role of pemetrexed combined with targeted agents for non-small cell lung cancer.

  Konopa K, Jassem J. Konopa K, et al. Curr Drug Targets. 2010 Jan;11(1):2-11. doi: 10.2174/138945010790030965. Curr Drug Targets. 2010. PMID: 19839932 Review.

• Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.

  Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S, Simms L, Saxman S. Kim ES, et al. Lancet Oncol. 2013 Dec;14(13):1326-36. doi: 10.1016/S1470-2045(13)70473-X. Epub 2013 Nov 12. Lancet Oncol. 2013. PMID: 24231627 Clinical Trial.

• Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer.

  Li T, Lara PN Jr, Mack PC, Perez-Soler R, Gandara DR. Li T, et al. Curr Drug Targets. 2010 Jan;11(1):85-94. doi: 10.2174/138945010790030983. Curr Drug Targets. 2010. PMID: 19839922 Review.

• Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.

  Choi MK, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS. Choi MK, et al. Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3. Cancer Chemother Pharmacol. 2014. PMID: 24696125

• Pemetrexed in advanced non-small cell lung cancer.

  Gridelli C, Maione P, Rossi A, Bareschino MA, Schettino C, Sacco PC, Zeppa R. Gridelli C, et al. Expert Opin Drug Saf. 2011 Mar;10(2):311-7. doi: 10.1517/14740338.2011.553281. Epub 2011 Jan 25. Expert Opin Drug Saf. 2011. PMID: 21261558 Review.

Cited by

• The emerging treatment landscape of targeted therapy in non-small-cell lung cancer.

  Yuan M, Huang LL, Chen JH, Wu J, Xu Q. Yuan M, et al. Signal Transduct Target Ther. 2019 Dec 17;4:61. doi: 10.1038/s41392-019-0099-9. eCollection 2019. Signal Transduct Target Ther. 2019. PMID: 31871778 Free PMC article. Review.

• Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer.

  Hijazo-Pechero S, Alay A, Marín R, Vilariño N, Muñoz-Pinedo C, Villanueva A, Santamaría D, Nadal E, Solé X. Hijazo-Pechero S, et al. Cancers (Basel). 2021 Sep 22;13(19):4734. doi: 10.3390/cancers13194734. Cancers (Basel). 2021. PMID: 34638221 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ingenta plc

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal